Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, ...
AstraZeneca is getting ready to step on the gas in the world of bispecific T cell engagers. The company presented some of its ...
Legislation targeting popular Chinese biotech contractors like WuXi AppTec wasn't included in must-pass defense legislation ...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday ...
The usual enhanced security measures are expected to be in place in San Francisco next month when the healthcare industry ...
BioAge Labs is scrapping a Phase 2 trial testing its anti-obesity drug, a few months after its flashy $198 million initial ...
Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, ...
AstraZeneca and Daiichi Sankyo have unveiled new data on their TROP2-directed ADC in pretreated lung cancer patients with ...
Despite months of biopharma industry pushback, the European Commission has unconditionally approved Novo Holdings’ $16.5 ...
A UK political committee says the country is underprepared for future pandemics due to 'worrying developments' on domestic ...
The same day that National Resilience announced a new CEO, it said that it will cut more than 100 jobs in Florida. The ...
GSK's BD team was busy leading up to the Thanksgiving holiday. In the last two days, the UK-based pharma has announced three ...